Prognosis
Trump Investing Millions to Bring Drugmaking Back to U.S.
- U.S. to streamline drugmaking with ‘substantial investments’
- Concentration of drug making in China, India been a concern
This article is for subscribers only.
The Trump administration plans to pump millions of dollars into producing more medications in the U.S. as the coronavirus pandemic heightens longstanding concerns about the fragility of the global drug supply chain.
On Tuesday, the Biomedical Advanced Research and Development Authority awarded a $345 million contract to a group led by Virginia-based drug company Phlow Corp. to make medicines that have fallen into short supply. BARDA is an agency within the Department of Health and Human Services that’s responsible for developing medical countermeasures to emergencies.